enGene Therapeutics, Inc. (ENGN)
1.81
+0.03
(+1.69%)
USD |
NASDAQ |
Aug 24, 16:00
1.82
+0.01
(+0.55%)
After-Hours: 20:00
enGene Therapeutics Debt to Equity Ratio : 0.1307 for April 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| April 30, 2026 | 0.1307 |
| January 31, 2026 | 0.1189 |
| October 31, 2025 | 0.1896 |
| July 31, 2025 | 0.1564 |
| April 30, 2025 | 0.1116 |
| January 31, 2025 | 0.1006 |
| October 31, 2024 | 0.0918 |
| July 31, 2024 | 0.1079 |
| April 30, 2024 | 0.1016 |
| January 31, 2024 | 0.3931 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0338 |
| July 31, 2023 | 0.00 |
| June 30, 2023 | 0.0198 |
| March 31, 2023 | 0.0035 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Aurinia Pharmaceuticals, Inc. | 0.1043 |
| Medicus Pharma Ltd. | -12.27 |
| Sirona Biochem Corp. | -- |
| Xenon Pharmaceuticals, Inc. | 0.0052 |
| Psyence Biomedical Ltd. | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 307.52M |
| Total Liabilities (Quarterly) | 52.36M |
| Shareholders Equity (Quarterly) | 255.17M |
| Current Ratio | 12.57 |
| Net Debt Paydown Yield | -0.34% |